CC
EWTX icon

Centiva Capital’s Edgewise Therapeutics EWTX Stock Holding History

Centiva Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.4K Buy
1,217
+678
+126% +$23.4K ﹤0.01% 1624
2026
Q1 		$17K Sell
539
-11,961
-96% -$345K ﹤0.01% 1565
2025
Q4 		$310K Buy
+12,500
New +$251K ﹤0.01% 840

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Centiva Capital's EWTX Position: Q2 2026 in Review

Centiva Capital increased its Edgewise Therapeutics (EWTX) stake by 126% in Q2 2026, buying an estimated $23.4K and bringing the position to 1,217 shares worth $49.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Centiva Capital first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $310K in Q4 2025. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Centiva Capital held 1,217 shares of Edgewise Therapeutics worth $49.4K as of Q2 2026.
  • Centiva Capital bought 678 Edgewise Therapeutics shares in Q2 2026, an estimated $23.4K.
  • Edgewise Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1624 holding.
  • Centiva Capital first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Centiva Capital's Edgewise Therapeutics position peaked at $310K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.